Melanotan II has been administered in small human studies and shows biological activity, but it is not an approved medicine and long-term safety is uncertain. Cosmetic or sexual-use claims go beyond what the limited evidence can establish.
Still uncertain: Long-term cosmetic or sexual-function benefit, long-term safety, safe self-use or an approved regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Cyclic melanocortin peptide analogue
Entity type
Peptide analogue / modified peptide
Research focus
Pigmentation and sexual-function research
Human evidence
Very small human studies demonstrate pigmentation and erectogenic/sexual-desire effects, including placebo-controlled ED studies, but these do not establish routine therapeutic or cosmetic use.
Regulatory status
Not FDA-approved as a tanning medicine; FDA lists significant safety concerns for compounded Melanotan II.
Main limitations
Long-term cosmetic/sexual efficacy, chronic safety, safe self-use or an approved regimen.
Safety
Nausea, somnolence, spontaneous erections/priapism and other effects; FDA notes serious case reports including melanoma, PRES and sympathomimetic toxidrome, without implying all are causal.
Evidence reviewed
2026-09-18
i
Very small human studies demonstrate pigmentation and erectogenic/sexual-desire effects, including placebo-controlled ED studies, but these do not establish routine therapeutic or cosmetic use.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Nausea, somnolence, spontaneous erections/priapism and other effects; FDA notes serious case reports including melanoma, PRES and sympathomimetic toxidrome, without implying all are causal.
Nausea is common in early studies; FDA summarizes serious case-report signals including melanoma, priapism, sympathomimetic toxidrome and posterior reversible encephalopathy syndrome. Product quality is an additional risk.
Technical details
Mechanism / biologyAgonist at melanocortin receptors, producing melanogenic and other central effects.
Route / formulation boundarySmall research trials do not establish safety of internet-sourced tanning products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published Phase I human regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
5outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
